Compare EGY & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | ACHV |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.8M | 618.0M |
| IPO Year | 1996 | 2018 |
| Metric | EGY | ACHV |
|---|---|---|
| Price | $5.44 | $6.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.30 | ★ $14.67 |
| AVG Volume (30 Days) | 1.5M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $29.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $2.38 |
| 52 Week High | $6.72 | $7.11 |
| Indicator | EGY | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 60.23 |
| Support Level | $5.04 | $4.09 |
| Resistance Level | $5.58 | $7.11 |
| Average True Range (ATR) | 0.19 | 0.44 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 84.17 | 53.70 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.